Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Claude Barbare

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Oncology Reports|December 21, 2018
Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinomaCorinne Godin, Sandra Bodeau, Zuzana Saidak, et al.
Journal of Hepatology|November 27, 2012
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinomaMomar Diouf, Thomas Filleron, Jean-Claude Barbare, et al.
Gastroenterologie Clinique Et Biologique|August 24, 2002
[Practical screening and early treatment of hepatocellular carcinoma. Results of a French survey]Nathalie Ganne-Carrié, Sylvie Chevret, Jean-Claude Barbare, et al.
Bulletin Du Cancer|February 13, 2009
[Management of hepatocellular carcinoma. Where are we now? What's next?]Julien Taieb, Jean-Claude Barbare, Tarek Boussaha, et al.
International Journal of Cancer|April 20, 2012
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenibZakaria Ezzoukhry, Christophe Louandre, Eric Trécherel, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 12, 2008
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trialsFranck Bonnetain, Xavier Paoletti, Sandra Collette, et al.
Bulletin Du Cancer|June 6, 2014
[Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?]Jean-Claude Barbare, Dominique Franco, Thierry André, et al.
Cancer Letters|December 3, 2014
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cellsChristophe Louandre, Ingrid Marcq, Hicham Bouhlal, et al.
Journal of Hepatology|November 5, 2010
Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative settingCaroline Tournoux-Facon, Xavier Paoletti, Jean-Claude Barbare, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Randomized controlled trial of tamoxifen in advanced hepatocellular carcinomaJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Oncology Reports|December 21, 2018
Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinomaCorinne Godin, Sandra Bodeau, Zuzana Saidak, et al.
Journal of Hepatology|November 27, 2012
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinomaMomar Diouf, Thomas Filleron, Jean-Claude Barbare, et al.
Gastroenterologie Clinique Et Biologique|August 24, 2002
[Practical screening and early treatment of hepatocellular carcinoma. Results of a French survey]Nathalie Ganne-Carrié, Sylvie Chevret, Jean-Claude Barbare, et al.
Bulletin Du Cancer|February 13, 2009
[Management of hepatocellular carcinoma. Where are we now? What's next?]Julien Taieb, Jean-Claude Barbare, Tarek Boussaha, et al.
International Journal of Cancer|April 20, 2012
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenibZakaria Ezzoukhry, Christophe Louandre, Eric Trécherel, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 12, 2008
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trialsFranck Bonnetain, Xavier Paoletti, Sandra Collette, et al.
Bulletin Du Cancer|June 6, 2014
[Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?]Jean-Claude Barbare, Dominique Franco, Thierry André, et al.
Cancer Letters|December 3, 2014
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cellsChristophe Louandre, Ingrid Marcq, Hicham Bouhlal, et al.
Journal of Hepatology|November 5, 2010
Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative settingCaroline Tournoux-Facon, Xavier Paoletti, Jean-Claude Barbare, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Randomized controlled trial of tamoxifen in advanced hepatocellular carcinomaJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Pageof 4